他喹莫德联合方案治疗进展期骨髓增殖性肿瘤急变期的临床前疗效
本研究在进展期骨髓增殖性肿瘤(MPN)细胞系及患者来源CD34+急变期(外周血原始细胞>5%)细胞中评估他喹莫德(TQ)的临床前疗效,发现TQ可降低细胞活力和干祖细胞标志物表达,与芦可替尼或BET抑制剂联用产生协同致死效应,并在PDX小鼠中显著改善生存。
要点
- TQ降低MPN细胞系和患者来源MPN-BP细胞活力,对正常CD34+祖细胞无此作用。
- TQ与芦可替尼或BET抑制剂联用对进展期MPN-BP细胞产生协同致死效应。
- TQ单药及与芦可替尼或OTX015联用均显著改善PDX小鼠生存。
核心结论
- 这些发现明确证明TQ在进展期MPN-BP细胞中具有临床前疗效,并为进一步探究TQ联合当前一线疗法或新型药物在伴原始细胞增多的进展期MPN中的疗效提供了依据。
研究设计与样本
- 临床前研究,在进展期MPN细胞系和患者来源CD34+急变期(外周血原始细胞>5%)MPN细胞中评估TQ的疗效。
- 使用免疫缺陷NOD scid gamma(NSG)小鼠移植患者来源异种移植(PDX)细胞进行体内实验。
主要发现
- TQ诱导细胞系和患者来源MPN-BP细胞活力丧失,但不诱导正常CD34+祖细胞活力丧失。
- 在TQ处理的患者来源MPN-AML细胞中,RNA测序分析显示MYC和E2F靶基因集、白细胞介素6-JAK-STAT3信号及炎症反应基因集呈负富集。
- 在表型定义的患者来源CD34+ MPN-BP干祖细胞中,飞行时间流式分析显示TQ降低包括A8、A9和髓过氧化物酶在内的蛋白表达,同时增加生长因子独立因子1(GFI1)、p21和切割型多聚(ADP-核糖)聚合酶(PARP)的表达。
- TQ与芦可替尼或BET抑制剂共处理在进展期MPN-BP细胞中诱导协同致死效应。
- 在移植MPN-AML患者来源PDX细胞的免疫缺陷NSG小鼠中,TQ单药治疗显著改善生存;TQ与芦可替尼或OTX015共处理较单药治疗显著改善生存。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The alarmins, S100A8 (A8) and S100A9 (A9), are low molecular weight proteins belonging to the S100 protein family. A8 and A9 are secreted into the extracellular space and plasma, in which they interact with Toll-like receptor 4, receptor for advanced glycation end products, and CD33. In these studies, we determined the preclinical efficacy of tasquinimod (TQ) against advanced myeloproliferative neoplasm (MPN) cell lines and patient-derived (PD) CD34+ blastic phase (BP; >5% blasts in the peripheral blood) MPN cells. TQ induced loss of viability in cell lines and PD MPN-BP cells, but not in normal CD34+ progenitor cells. In TQ-treated PD MPN-acute myeloid leukemia (AML) cells, RNA-sequencing analysis showed negative enrichment of the gene sets of MYC and E2F targets, interleukin-6-JAK-STAT3 signaling, and of inflammatory response. In phenotypically defined, PD CD34+ MPN-BP stem progenitor cells, cytometry by time-of-flight analysis showed that TQ reduced expression of proteins including A8, A9, and myeloperoxidase, while increasing expression of Growth Factor Independence 1 (GFI1), p21, and cleaved Poly(ADP-ribose) polymerase (PARP). Cotreatment with TQ and ruxolitinib or Bromodomain and extraterminal domain (BET) inhibitor induced synergistic lethality in advanced MPN-BP cells. Monotherapy with TQ significantly improved survival of immune-depleted NOD scid gamma (NSG) mice engrafted with PD xenograft (PDX) cells of MPN-AML. Notably, cotreatment with TQ and ruxolitinib or OTX015 induced significantly greater survival than treatment with single agents in the NSG mice engrafted with the PDX cells. These findings clearly demonstrate the preclinical efficacy of TQ in advanced MPN-BP cells and create the rationale to further interrogate the efficacy of TQ-based combinations with the current, frontline therapies or novel agents in advanced MPNs with excess blasts.
引用
- Fiskus W, Masarova L, Mill CP, et al. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv. 2025. PMID: 40829105. doi:10.1182/bloodadvances.2025016898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。